Aignostics is at the forefront of precision medicine, utilizing advanced artificial intelligence (AI) technologies to transform complex biomedical data into actionable insights. Their flagship offering is a foundation model for histopathology, developed through a unique "pathologist-in-the-loop" approach that enhances model robustness and performance. This model is trained on a vast and diverse dataset, including over 133,000 slides and 1.2 billion image patches, which allows it to achieve over 90% accuracy on key histopathology benchmarks. Aignostics' technology not only improves the accuracy of downstream tasks but also significantly reduces the amount of training data required, making it a powerful tool for biopharma in drug development and clinical trials.

In addition to their foundation model, Aignostics employs patented technologies such as "Explainable AI" and "Label Extraction," which enhance the interpretability and scalability of their AI solutions. Their platform integrates high-quality multimodal pathology data, including standard and emerging modalities, to support comprehensive analysis in translational research and clinical diagnostics. Aignostics is committed to regulatory excellence, having achieved ISO 13485 certification for its quality management system, which underscores its dedication to maintaining the highest standards in product quality and information security. This combination of cutting-edge technology, robust data access, and a strong scientific foundation positions Aignostics as a leader in the AI-powered healthcare landscape.

Germany

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

Aignostics

Company Details